drugset / Trial / NCT03439475

AMG 714 Expanded Access Program

NCT03439475 ↗

Expanded access No longer available Amgen

Summary

Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background ORDESEKIMAB Monoclonal antibody — —

Indications